Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/31 cls
Anadys (ANDS) Cowen Eric Schmidt Downgrade Neutral(from market outperform) -7% $2.25
Schmidt cited a lack of near-term milestones. In July, ANDS and partner Novartis (NVS; SWX:NOVN) dropped ANA975 to treat HCV, and last month, ANDS returned rights to ANA380 to treat HBV to LG Life Sciences (see BioCentury, July 30 & Aug. 6).
Charles River (CRL)

Read the full 696 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE